Skip to main content
. Author manuscript; available in PMC: 2019 Jan 22.
Published in final edited form as: JACC Cardiovasc Interv. 2017 Nov 1;11(2):181–191. doi: 10.1016/j.jcin.2017.07.022

FIGURE 2, CENTRAL ILLUSTRATION. Outcomes with Clinical Implementation of CYP2C19-Guided Antiplatelet Therapy after PCI.

FIGURE 2, CENTRAL ILLUSTRATION

Data are shown for patients with a CYP2C19 loss-of-function (LOF) allele treated with clopidogrel (LOF-Clopidogrel), patients with a LOF allele treated with alternative antiplatelet drug therapy (LOF-Alternative), and patients without an LOF allele treated with either clopidogrel or alternative therapy (non-LOF). The unadjusted log-rank p-values for the LOF-Clopidogrel group compared to LOF-Alternative group and for the Non-LOF group compared to the LOF-Alternative group are provided. LOF, loss-of-function; MACE, major adverse cardiovascular events